Apogee Therapeutics Plans To Highlight Updates From Across Its Pipeline During Virtual R&D Day
Apogee Therapeutics Plans To Highlight Updates From Across Its Pipeline During Virtual R&D Day
Apogee Therapeutics計劃在虛擬研發日活動中重點介紹其全球範圍內的最新進展
Updates include interim results from the APG808 Phase 1 trial, data up to 12 months from the APG777 Phase 1 trial, details around the Company's strategy for combinations in AD, asthma and COPD to deliver better efficacy and dosing regimens, and the expected significant commercial potential of its programs.
更新包括APG808相位1試驗的中期結果，APG777相位1試驗長達12個月的數據，公司在AD、哮喘和COPD組合策略方面的詳細信息，以提供更好的療效和給藥方案，以及其項目預期的顯著商業潛力。
Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing.
長達12個月的數據強化了APG777的最佳潛力，包括77天的半衰期，並提供了年度用藥的潛在途徑。